Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Andrew Sims is Vice President and Chief Financial Officer at Plus Therapeutics, Inc. Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price.
Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.
Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at Plus Therapeutics, Inc. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics.
Mr. Havranek has over 26 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded, biopharma and medical device companies. His prior roles in marketing, strategy, business development, general management, and R&D focused on the oncology, rare disease, cardiology, and orthopedic markets. These roles were held at Johnson & Johnson, Guidant (now Abbott), Genentech (now Roche), DJO Global (now Enovis), Volcano (now Philips), and CareFusion (now Becton Dickinson).
Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.
Dr. Rosol has 25 years of experience in preclinical and clinical research, trial design, operations, and regulatory execution. Most recently, he served as Chief Executive Officer of Atherion Bioresearch, a Contract Research Organization specializing in the radiopharmaceutical and radiotherapeutics space. Prior to this, he was Chief Medical Officer and Senior Vice President at Navidea Biopharmaceuticals, where he led the company’s clinical research and development programs. Before these roles, Dr. Rosol worked at Novartis Pharmaceuticals, leading key biomarker development and translational imaging groups.
Dr. Rosol holds a Ph.D. from the Boston University School of Medicine and has held various academic appointments at Harvard Medical School/Massachusetts General Hospital, the Mayo Clinic, Children’s Hospital of Los Angeles/USC Keck School of Medicine, and the Medical University of South Carolina.
Mr. Bradley is currently President and General Manager, CNSide Diagnostics, LLC. Previously, Mr. Bradley led the Hematology Business Unit at Abbott Laboratories (NYSE: ABT) as General Manager. Before joining Abbott Labs, Mr. Bradley served as Senior Vice President of Corporate Development and Chief Marketing and Sales Officer of Luminex, Inc. (NASDAQ: LMNX – acquired by Diasorin for $1.8B in 2021). Previously, Mr. Bradley spent 17 years at Beckman Coulter, Inc. (acquired by Danaher (NYSE: DHR) for $6.8B), where he served in roles of increasing responsibility, including global commercial leadership of Beckman Coulter’s flow cytometry business and as the director of the Beckman Coulter CARES initiative, leading the company’s HIV clinical monitoring business in developing regions around the globe. During his tenure as a senior executive in the life science and clinical diagnostics markets, Mr. Bradley has completed the evaluation, market assessment, and successful commercial launch of multiple clinical diagnostics and life science technologies. Mr. Bradley obtained a B.Sc. Immunology and Biochemistry from Monash University, Melbourne, Australia.
